Cargando…

HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia

Infant t(4;11) acute lymphoblastic leukemia is the most common leukemia in infant patients and has a highly aggressive nature. The patients have a dismal prognosis, which has not improved in more than a decade, suggesting that a better understanding of this disease is required. In the study describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Symeonidou, Vasiliki, Ottersbach, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851112/
https://www.ncbi.nlm.nih.gov/pubmed/33069783
http://dx.doi.org/10.1016/j.exphem.2020.10.002
_version_ 1783645577216524288
author Symeonidou, Vasiliki
Ottersbach, Katrin
author_facet Symeonidou, Vasiliki
Ottersbach, Katrin
author_sort Symeonidou, Vasiliki
collection PubMed
description Infant t(4;11) acute lymphoblastic leukemia is the most common leukemia in infant patients and has a highly aggressive nature. The patients have a dismal prognosis, which has not improved in more than a decade, suggesting that a better understanding of this disease is required. In the study described here, we analyzed two previously published RNA-sequencing data sets and gained further insights into the global transcriptomes of two known subgroups of this disease, which are characterized by the presence or absence of a homeobox gene expression signature. Specifically, we identified a remarkable mutually exclusive expression of the HOXA9/HOXA10 and IRX1 genes and termed the two subgroups iALL-HOXA9 and iALL-IRX1. This expression pattern is critical as it suggests that there is a fundamental difference between the two subgroups. Investigation of the transcriptomes of the two subgroups reveals a more aggressive nature for the iALL-IRX1 group, which is further supported by the fact that patients within this group have a worse prognosis and are also diagnosed at a younger age. This could be reflective of a developmentally earlier cell of origin for iALL-IRX1. Our analysis further uncovered critical differences between the two groups that may have an impact on treatment strategies. In summary, after a detailed investigation into the transcriptional profiles of iALL-HOXA9 and iALL-IRX1 patients, we highlight the importance of acknowledging that these two subgroups are different and that this is of clinical importance.
format Online
Article
Text
id pubmed-7851112
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Science Inc
record_format MEDLINE/PubMed
spelling pubmed-78511122021-02-04 HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia Symeonidou, Vasiliki Ottersbach, Katrin Exp Hematol Brief Communication Infant t(4;11) acute lymphoblastic leukemia is the most common leukemia in infant patients and has a highly aggressive nature. The patients have a dismal prognosis, which has not improved in more than a decade, suggesting that a better understanding of this disease is required. In the study described here, we analyzed two previously published RNA-sequencing data sets and gained further insights into the global transcriptomes of two known subgroups of this disease, which are characterized by the presence or absence of a homeobox gene expression signature. Specifically, we identified a remarkable mutually exclusive expression of the HOXA9/HOXA10 and IRX1 genes and termed the two subgroups iALL-HOXA9 and iALL-IRX1. This expression pattern is critical as it suggests that there is a fundamental difference between the two subgroups. Investigation of the transcriptomes of the two subgroups reveals a more aggressive nature for the iALL-IRX1 group, which is further supported by the fact that patients within this group have a worse prognosis and are also diagnosed at a younger age. This could be reflective of a developmentally earlier cell of origin for iALL-IRX1. Our analysis further uncovered critical differences between the two groups that may have an impact on treatment strategies. In summary, after a detailed investigation into the transcriptional profiles of iALL-HOXA9 and iALL-IRX1 patients, we highlight the importance of acknowledging that these two subgroups are different and that this is of clinical importance. Elsevier Science Inc 2021-01 /pmc/articles/PMC7851112/ /pubmed/33069783 http://dx.doi.org/10.1016/j.exphem.2020.10.002 Text en Crown Copyright © 2020 Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Communication
Symeonidou, Vasiliki
Ottersbach, Katrin
HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia
title HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia
title_full HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia
title_fullStr HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia
title_full_unstemmed HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia
title_short HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia
title_sort hoxa9/irx1 expression pattern defines two subgroups of infant mll-af4-driven acute lymphoblastic leukemia
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851112/
https://www.ncbi.nlm.nih.gov/pubmed/33069783
http://dx.doi.org/10.1016/j.exphem.2020.10.002
work_keys_str_mv AT symeonidouvasiliki hoxa9irx1expressionpatterndefinestwosubgroupsofinfantmllaf4drivenacutelymphoblasticleukemia
AT ottersbachkatrin hoxa9irx1expressionpatterndefinestwosubgroupsofinfantmllaf4drivenacutelymphoblasticleukemia